Adam L. Boxer, MD, PhD is the Endowed Professor in Memory and Aging in the Department of Neurology at the University of California, San Francisco (UCSF). He received his MD and PhD from the New York University Medical Center Medical Scientist Training Program, completed a Neurology Residency at Stanford and a Neurobehavior Fellowship at UCSF. Dr. Boxer directs the Neurosciences Clinical Research Unit and the Alzheimer’s Disease and Frontotemporal Degeneration (FTD) Clinical Trials Program at the UCSF Memory and Aging Center.

Dr. Boxer has been a pioneer in developing new treatments and biomarkers for frontotemporal lobar degeneration. He is co-Principal Investigator of the ARTFL/LEFFTDS Longitudinal Frontotemporal Lobar Degeneration (ALLFTD) project, a 27 site research network focused on preparing for FTLD clinical trials, and the FTD Prevention Initiative (FPI), a global collaboration focused on preparing for prevention trials in autosomal dominant FTLD. He is PI of the Neurofilament Surveillance Project (NSP), a privately funded study that is developing blood biomarkers for use in FTLD clinical trials.

He also leads the Four Repeat Tauopathy Neuroimaging Initiative (4RTNI), a NIH-funded, multicenter, longitudinal tau PET and biomarker study focused on PSP and CBD. He has been the PI for a variety of multicenter, randomized, placebo controlled clinical trials in neurodegenerative diseases, including memantine for FTLD, davunetide for PSP, TPI-287 for primary and secondary tauopathies, a Phase 1b trial of gosuranemab for PSP, and salsalate for Alzheimer’s Disease and PSP. He has co-chaired the National Alzheimer’s Project Act (NAPA) FTLD Research Committee for the past four years. He also co-chairs the FTLD Research Roundtable and the PSP Research Roundtable, academic-industry collaborative groups working to speed the development of new therapies for FTLD, CBD and PSP.